Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 13 JANUARY 2023

For SEC, What's Old Is (Refreshed) Again

Holland & Knight
Explore more from Holland & Knight

The U.S. Securities and Exchange Commission (SEC) on Jan. 4, 2023, released its Fall 2022 Unified Agenda of Regulatory and Deregulatory Actions (Reg Flex Agenda).

United StatesCorporate/Commercial Law
Paul Monsour
Paul Monsour
Shawn M. Turner
Shawn M. Turner
Ira Rosner
Ira Rosner
Author LinkedIn connections

Highlights

  • The U.S. Securities and Exchange Commission (SEC) on Jan. 4, 2023, released its Fall 2022 Unified Agenda of Regulatory and Deregulatory Actions (Reg Flex Agenda). The SEC's Reg Flex Agenda is released semiannually and, notwithstanding the back-dated title, lists the rulemakings that the SEC plans to consider in the short- and long-term time frames.
  • The Fall 2022 Reg Flex Agenda is divided by rulemaking stage: 1) Proposed, 2) Final and 3) Adopted. The Appendix shows changes since the publication of the Spring 2022 Reg Flex Agenda.
  • Registrants will need to stay abreast of the rulemakings and ensure that they are prepared for any new reporting obligations.

The U.S. Securities and Exchange Commission (SEC) on Jan. 4, 2023, released its Fall 2022 Unified Agenda of Regulatory and Deregulatory Actions (Reg Flex Agenda). The SEC's Reg Flex Agenda is released semiannually and, notwithstanding the back-dated title, lists the rulemakings that the SEC

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Healthcare Trends & Transactions Q2 2026

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.
United StatesCorporate/Commercial Law
Bass, Berry & Sims PLC
Bass, Berry & Sims PLC
Article

CLIENT ALERT: 2026 Mid-Year Update On SEC And CFTC Enforcement

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.
United StatesCorporate/Commercial Law
Sher Tremonte
Sher Tremonte
Article

Sanofi And Regeneron Expand Immunology Collaboration In Deal Worth Up To $8 Billion

Sanofi and Regeneron Pharmaceuticals announce a major expansion of their immunology partnership, committing up to $8 billion to develop and commercialize four long-acting antibodies targeting key inflammatory pathways. The collaboration includes a $1 billion upfront payment and milestone-based payments, with both companies sharing development costs and future profits equally.
United StatesCorporate/Commercial Law
Goodwin Procter LLP
Goodwin Procter LLP